Abiomed

Abiomed develops medical devices for circulatory and oxygenation support, primarily its Impella heart pumps. These advanced devices aid patients experiencing severe cardiac conditions like cardiogenic shock, high-risk percutaneous coronary intervention, and right heart failure, employing sophisticated technology to facilitate native heart recovery. Their technical approach centers on miniaturized, percutaneous heart pumps that provide temporary cardiac assistance.

Established in 1981 by David M. Lederman, Abiomed initially pursued the groundbreaking objective of creating the world's first artificial heart. This pioneering vision addressed a profound medical need for advanced cardiac assistance. The company's focus subsequently evolved, building on its mechanical circulatory support foundation to prioritize natural heart recovery, shifting from replacement to rehabilitation.

Healthcare professionals globally utilize Abiomed's products to treat patients needing temporary mechanical circulatory support for various critical cardiac indications. The company’s vision focuses on enhancing patient outcomes by continually advancing its technology to recover hearts, oxygenate the body, and save lives, ultimately redefining cardiac care standards through ongoing innovation.